HealthCare Royalty
RegenXBio Secures Up to $250 Million by Monetizing Royalties from Zolgensma and Two Gene Therapies
RegenXBio; Zolgensma; gene therapy; royalty monetization; HealthCare Royalty; RGX-121; RGX-111; non-dilutive financing; biotech; milestone payments